Child and parent psychological problems influence child weight control

This study used path analytic methods to assess the influence of child psychopathology measured using the Child Behavior Checklist and parent psychiatric symptoms measured using the Cornell Medical Index on changes in child percent overweight in obese 8- to 11-year-old children over 2 years (6 months of treatment, 18 months of follow-up) provided family-based behavioral intervention. Path analysis for the 0-6 month change showed the influence of mother and father psychiatric symptoms and child age on child anxiety/depression scores that in turn influenced child percent overweight change during treatment, accounting for 41% of the shared variance. The path analysis for follow-up change showed mother and father psychiatric symptoms influenced child social problems at the first stage, and child social problems influenced child percent overweight change, accounting for 68.5% of the shared variance. These results provide the first demonstration that both parent and child problems may influence the short- and long-term success of obese children who participate in family-based behavioral treatment programs.     

小鼠颗粒子宫腺细胞的组织学与超微结构的研究

对昆明种小鼠颗粒子宫腺细胞（ＧＭＧ细胞）进行光镜及电镜观察,结果显示：ＧＭＧ细胞以其胞浆中含耐淀粉酶消化的ＰＡＳ阳性颗粒为特点,而该种颗粒在电镜下为带有帽状结构的膜包颗粒。ＧＭＧ细胞有特殊的形态,其出现和消失与妊娠过程同步。     

N-端融合蛋白对重组HBeAg抗原性的影响

目的　研究 Ｎ－ 末端融合蛋白对大肠杆菌中表达的 Ｈ Ｂｅ Ａｇ 抗原性的影响。方法　用 Ｐ Ｃ Ｒ 法,从抗－ Ｈ Ｂｃ（ ＋ ） 血清标本中获得 Ｈ Ｂ Ｖ Ｐｒｅ ｃ － ｃ 基因片段,将其插入质粒 Ｔｒｃ９９ Ａ,重组成亚克隆 Ｐ Ｈ Ｂ Ｉ。以 Ｐ Ｈ Ｂ Ｉ为模板,扩增获得编码乙肝病毒核心蛋白１ ～１４０ 氨基酸的基因片段,加上终止信号,分别插入质粒ｐ Ｇ Ｅ Ｘ－ ２ Ｔ 和 Ｔｒｃ９９ Ａ 中,各自转化后,以 Ｉ Ｐ Ｔ Ｇ 诱导,大肠杆菌表达插入基因。以 Ｅ Ｌ Ｉ Ｓ Ａ 和 Ｓ Ｄ Ｓ－ Ｐ Ａ Ｇ Ｅ 方法测定表达产物的分子量和 Ｈ Ｂｅ Ａｇ 、 Ｈ Ｂｃ Ａｇ 滴度。结果　在 Ｉ Ｐ Ｔ Ｇ 诱导下,大肠杆菌中分别表达 Ｎ－ 端融合的 Ｇ Ｓ Ｔ－ Ｈ Ｂｅ Ａｇ 融合蛋白和非融合 Ｈ Ｂｅ Ａｇ 蛋白。分子量各为４１０００ Ｄ 和１５０００ Ｄ。培养裂解物经 Ｅ Ｌ Ｉ Ｓ Ａ 测定,融合蛋白 Ｈ Ｂｅ Ａｇ ： Ｈ Ｂｃ Ａｇ 的滴度比为２５６ ：１ ,非融合蛋白为１６ ：１ 。结论　 Ｎ－ 端融合蛋白 Ｇ Ｓ Ｔ－ Ｈ Ｂｅ Ａｇ 抗原性更接近血清 Ｈ Ｂｅ Ａｇ 。     

Preliminary study on HA coating percutaneously implanted in bone

A comparative investigation on the possibility of hydroxyapatite (HA) coating and pure Ti column to form biological sealing with skin tissue was completed in this study. HA coating and pure Ti column were percutaneously implanted in the tibia of rabbits. Compared with titanium (Ti) implant, HA coating forms epithelial sealing with skin tissue at 6 weeks postoperatively, while the Ti implant may loosen from the implanted site and be lost. The Ti column loosing rate at this time was 50%. However, once the Ti implant becomes fixed with the bone tissue, it can form epithelial sealing with skin tissue just like the HA coating, at 8 weeks postoperatively. At 8 weeks postoperatively, the epithelial sealing is not destroyed in spite of the fact that the HA coating is biodegraded. Our results show that the HA coating can become fixed with the bone faster than the Ti, which is beneficial for epithelial sealing formation. The main role of HA coating for epithelial sealing is beneficial for sealing at the initial period after it is implanted.     

A single-incision technique to harvest subepithelial connective tissue grafts from the palate

This article describes a new and simplified surgical approach to harvest subepithelial connective tissue grafts from the palate. For this procedure, only a single incision parallel to the gingival margin is used to access the donor site for graft preparation and harvesting. Grafts of variable size and thickness can be obtained. Since no band of epithelium is removed with the connective tissue graft the palatal donor site can heal with primary intention. No stents or hemostatic agents are necessary to cover the donor area postoperatively, and suturing can be reduced to a minimum. The harvesting technique is illustrated step by step, and the clinical application of connective tissue grafts harvested with the proposed method is demonstrated with the coverage of a gingival recession.     

慢性肺心病急性发作期肺动脉高压治疗方法的系统研究

该研究系统观察了92例慢性肺心病急性发作期患使用4类6种血管扩张药物,其中包括硝普钠、氨力农、米力农、维拉帕米、地尔硫zhuo、卡托普剂,以及吸入低浓度一氧化氮和施行机械通气两种方式的治疗效果。并各自比较使用前后其血流动力学及氧动力学变化。观察结果表明,上述药物及方法均可有效地降低肺动脉压力、阻力,有良好的急性血流动力学效应及氧动力学效应。同时还分析了上述各种降压药物的作用特点和相应临床应用特征,对选择临床治疗方法有指导意义。     

Medium-term results of heart transplantation using donors over 63 years of age

BACKGROUND: The continual shortage of hearts for transplantation (HTx) led to the expansion of the donor pool by accepting older donors. We compared the medium-term follow-up of patients after HTx with older hearts (over the age of 63 years) with those of patients after HTx with younger hearts. PATIENTS AND METHODS: Since April 1994 we have used hearts for HTx from donors older than the age of 63 years. Until November 1998, 309 HTx and 9 re-HTx were performed in 309 adults with a mean age of 50.7+/-10.9 years (range 17-68 years). There were 252 men and 57 women. The patients were divided into two groups: group I--donor age under 63 years (296 patients, mean age 50.4+/-11 years; mean donor age 38.1+/-13 years; mean follow-up 1.7+/-1.6 years); group II-donor age of more than 63 years (13 patients, mean age 57.4+/-5.6 years; mean donor age 65.1+/-2.1; mean follow-up 2.2+/-1.6 years). There were no differences in the etiology of heart failure, gender, or ischemia time between the groups. The patients in group II were significantly older (P = 0.008). Multiple factors were analyzed in the groups, which included changes in the left/right ventricle ejection fraction, early postoperative mortality (up to 30 days), cumulative survival rates and cardiac-dependent morbidity [myocardial infarction, malignant arrhythmias, coronary stenosis (>50% in one of the main coronary arteries) and transplant vasculopathy]. Additionally, freedom from cytomegalovirus infection (rise of titer or seroconversion) and freedom of acute rejection episodes grade > or =2 (International Society of Heart & Lung Transplantation [ISHLT]) were analyzed. RESULTS: After 1 year mean left and right ventricle ejection fraction were good in both groups and did not significantly change for up to 2 years. No Re-HTx was performed in group II. The early postoperative mortality was similar in both groups (P = 0.8). Also, the cumulative survival rates were similar in both groups (P = 0.87). Long-term cardiac morbidity was lower in group I (P = 0.03). The long-term freedom from cytomegalovirus infection in group I was significantly higher when compared with group II (P = 0.0002). The long-term freedom from severe rejection episodes was similar in both groups (P = 0.3) CONCLUSION: The study found a significant increase in long-term cardiac morbidity due to more focal coronary stenosis in group II, and freedom from cytomegalovirus infection, but did not find significant differences in the long-term survival between patients who received hearts from donors of up to 63 years of age and from those more than 63 years. The acceptance of donors older than 63 years old for HTx does not worsen the outcome of the recipients. The careful selection of older donors, with close monitoring of the coronary situation after HTx and expanded indications for revascularization of older hearts, could make HTx with older hearts, even in older recipients, a safe option.     

Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1

BACKGROUND: Hematopoietic growth factors (HGF) can suppress chemotherapy-induced programmed cell death (apoptosis) in hematopoietic cells. Although HGF can modulate the expression of apoptosis-regulatory genes, including bcl-2, bax, and p21WAF1/CIP1 in cell lines, few data address whether HGF regulate the expression of these proteins in primary acute myeloid leukemia (AML). MATERIALS AND METHODS: We evaluated the expression of bcl-2, bax, and p21WAF1/CIP1 in primary samples from patients with AML in the presence and absence of HGF. The potential association of HGF-induced changes in the levels of these proteins with inhibition of chemotherapy-induced apoptosis was further investigated. RESULTS: While a combination of steel factor (SF) and PIXY321 inhibited etoposide-induced apoptosis in 8/11 primary AML samples studied, Bcl-2 and bax protein levels were unaffected by exposure to HGF and/or etoposide. In contrast, HGF enhanced basal and etoposide-induced p21WAF1/CIP1 protein levels in 9/11 and 7/11 of the cases, respectively. In several cases, inhibition of apoptosis by HGF was seen without up-regulation of p21WAF1/CIP1 levels, suggesting that modulation of p21WAF1/CIP1 is not required for HGF-mediated inhibition of apoptosis. CONCLUSIONS: These data indicate that HGF-mediated inhibition of chemotherapy-induced apoptosis in primary AML samples is not mediated through changes in Bcl-2, bax, and p21WAF1/CIP1 protein levels.     

Initial results of laser angioplasty under angioscopic guidance for salvage of an ischemic lower limb: preliminary report

From March to July 1989, nine patients at risk for peripheral artery disease underwent intraoperative Nd:YAG laser angioplasty using angioscopy at the Veterans General Hospital (Taipei, Taiwan, Republic of China). Following the laser angioplasty, balloon dilatation was performed in all cases. Eight men and one woman at an average age of 68 were included in the study (range: 58 to 78 years old). Ischemic symptoms included five patients with disabling claudication, four with pain at rest and one with gangrene on the toes. Eight of the nine patients had complete occlusions ranging from 2 to 19 cm in length. Two patients had high degree multiple segmental stenosis of the superficial femoral artery from 1 to 2 cm in length. Initial clinical success (indicated by relief of symptoms and increase in Doppler ankle pressure and index) and improvement in the angiographic luminal diameter was noted in 9 of 10 occluded vessels (90%) that underwent Nd:YAG laser treatment which was delivered at 10 to 12 watts through laser probes. Prelaser intraluminal diameter increased from 0.05 +/- 0.07 to 0.53 +/- 0.07 mm, Doppler ankle pressure index rose from 0.51 +/- 0.12 to 0.81 +/- 0.12, Doppler ankle pressure increased from 62.44 +/- 16.10 to 104 +/- 21.21 mmHg and the amplitude of pulse volume recorder at ankle level rose from 5.77 +/- 2.80 to 12.11 +/- 2.77 mm as compared with prelaser therapy (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)     

瘤内注射重组人p53腺病毒治疗晚期肺癌临床试验观察

目的 观察重组人p53腺病毒注射液(rAd-p53)在晚期肺癌治疗中的疗效和毒副反应。方法 12例IIIb-IV期肺癌及3例肺转移癌,CT定位经皮肺穿刺瘤内注射rAd-p53,1 次/周×4/疗程;通过临床观察、CT及病理对照及短期随访进行评价。结果 治疗后2 月观察肿瘤缩小5例(33.3%),无变化7例(46.7%),增大3例(20%);治疗后病理观察:癌组织坏死,癌细胞稀少(6/11,54.5%);除自限性发热外,无明显毒副反应。结论rAd-p53瘤内注射治疗肺癌,无明显毒副作用,能较好地抑制局部肿瘤的发展,尤其对失去手术机会,不能耐受放化疗的患者,是一种可行的有前景的方法。